138 related articles for article (PubMed ID: 28273130)
21. Open-label phase I clinical trial of Ad5-EBOV in Africans in China.
Wu L; Zhang Z; Gao H; Li Y; Hou L; Yao H; Wu S; Liu J; Wang L; Zhai Y; Ou H; Lin M; Wu X; Liu J; Lang G; Xin Q; Wu G; Luo L; Liu P; Shentu J; Wu N; Sheng J; Qiu Y; Chen W; Li L
Hum Vaccin Immunother; 2017 Sep; 13(9):2078-2085. PubMed ID: 28708962
[TBL] [Abstract][Full Text] [Related]
22. Perceptions and acceptability of an experimental Ebola vaccine among health care workers, frontline staff, and the general public during the 2014-2015 Ebola outbreak in Sierra Leone.
Jalloh MF; Jalloh MB; Albert A; Wolff B; Callis A; Ramakrishnan A; Cramer E; Sengeh P; Pratt SA; Conteh L; Hajjeh R; Bunnell R; Redd JT; Ekström AM; Nordenstedt H
Vaccine; 2019 Mar; 37(11):1495-1502. PubMed ID: 30755367
[TBL] [Abstract][Full Text] [Related]
23. Assessing the safety and immunogenicity of recombinant vesicular stomatitis virus Ebola vaccine in healthy adults: a randomized clinical trial.
ElSherif MS; Brown C; MacKinnon-Cameron D; Li L; Racine T; Alimonti J; Rudge TL; Sabourin C; Silvera P; Hooper JW; Kwilas SA; Kilgore N; Badorrek C; Ramsey WJ; Heppner DG; Kemp T; Monath TP; Nowak T; McNeil SA; Langley JM; Halperin SA;
CMAJ; 2017 Jun; 189(24):E819-E827. PubMed ID: 28630358
[TBL] [Abstract][Full Text] [Related]
24. Early trials of Ebola vaccine show immune response.
Mayor S
BMJ; 2015 Apr; 350():h1844. PubMed ID: 25855620
[No Abstract] [Full Text] [Related]
25. Safety and immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in children in Sierra Leone: a randomised, double-blind, controlled trial.
Afolabi MO; Ishola D; Manno D; Keshinro B; Bockstal V; Rogers B; Owusu-Kyei K; Serry-Bangura A; Swaray I; Lowe B; Kowuor D; Baiden F; Mooney T; Smout E; Köhn B; Otieno GT; Jusu M; Foster J; Samai M; Deen GF; Larson H; Lees S; Goldstein N; Gallagher KE; Gaddah A; Heerwegh D; Callendret B; Luhn K; Robinson C; Greenwood B; Leyssen M; Douoguih M; Leigh B; Watson-Jones D;
Lancet Infect Dis; 2022 Jan; 22(1):110-122. PubMed ID: 34529962
[TBL] [Abstract][Full Text] [Related]
26. Polyclonal and convergent antibody response to Ebola virus vaccine rVSV-ZEBOV.
Ehrhardt SA; Zehner M; Krähling V; Cohen-Dvashi H; Kreer C; Elad N; Gruell H; Ercanoglu MS; Schommers P; Gieselmann L; Eggeling R; Dahlke C; Wolf T; Pfeifer N; Addo MM; Diskin R; Becker S; Klein F
Nat Med; 2019 Oct; 25(10):1589-1600. PubMed ID: 31591605
[TBL] [Abstract][Full Text] [Related]
27. Safety, reactogenicity, and immunogenicity of a chimpanzee adenovirus vectored Ebola vaccine in adults in Africa: a randomised, observer-blind, placebo-controlled, phase 2 trial.
Tapia MD; Sow SO; Ndiaye BP; Mbaye KD; Thiongane A; Ndour CT; Mboup S; Ake JA; Keshinro B; Akintunde GA; Kinge TN; Vernet G; Bigna JJ; Oguche S; Koram KA; Asante KP; Hogrefe WR; Günther S; Naficy A; De Ryck I; Debois M; Bourguignon P; Jongert E; Ballou WR; Koutsoukos M; Roman F;
Lancet Infect Dis; 2020 Jun; 20(6):707-718. PubMed ID: 32199491
[TBL] [Abstract][Full Text] [Related]
28. Safety of the rVSV ZEBOV vaccine against Ebola Zaire among frontline workers in Guinea.
Juan-Giner A; Tchaton M; Jemmy JP; Soumah A; Boum Y; Faga EM; Cisse M; Grais RF
Vaccine; 2019 Nov; 37(48):7171-7177. PubMed ID: 30266489
[TBL] [Abstract][Full Text] [Related]
29. PREVAIL I Cluster Vaccination Study With rVSVΔG-ZEBOV-GP as Part of a Public Health Response in Liberia.
Bolay FK; Grandits G; Lane HC; Kennedy SB; Johnson MP; Fallah MP; Wilson B; Njoh WS; McNay LA; Hensley LE; Higgs ES
J Infect Dis; 2019 Apr; 219(10):1634-1641. PubMed ID: 30561672
[TBL] [Abstract][Full Text] [Related]
30. Attitudes about vaccines to prevent Ebola virus disease in Guinea at the end of a large Ebola epidemic: Results of a national household survey.
Irwin KL; Jalloh MF; Corker J; Alpha Mahmoud B; Robinson SJ; Li W; James NE; Sellu M; Jalloh MB; Diallo AA; Tracy L; Hajjeh R; VanSteelandt A; Bunnell R; Martel L; Raghunathan PL; Marston B;
Vaccine; 2017 Dec; 35(49 Pt B):6915-6923. PubMed ID: 28716555
[TBL] [Abstract][Full Text] [Related]
31. Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ça Suffit!).
Henao-Restrepo AM; Camacho A; Longini IM; Watson CH; Edmunds WJ; Egger M; Carroll MW; Dean NE; Diatta I; Doumbia M; Draguez B; Duraffour S; Enwere G; Grais R; Gunther S; Gsell PS; Hossmann S; Watle SV; Kondé MK; Kéïta S; Kone S; Kuisma E; Levine MM; Mandal S; Mauget T; Norheim G; Riveros X; Soumah A; Trelle S; Vicari AS; Røttingen JA; Kieny MP
Lancet; 2017 Feb; 389(10068):505-518. PubMed ID: 28017403
[TBL] [Abstract][Full Text] [Related]
32. Perceptions, attitudes, and willingness of healthcare and frontline workers to participate in an Ebola vaccine trial in Uganda.
Kimbugwe G; Vatrinet R; Mwanga JA; Kakuru R; Mpeirwe D; Logoose S; Opio K; Kambale M; Seeley J; Grais RF; Marquer C; Kaleebu P; Ssali A
Vaccine; 2024 Apr; 42(12):3002-3008. PubMed ID: 38565464
[TBL] [Abstract][Full Text] [Related]
33. Can Ebola Virus Vaccines Have Universal Immune Correlates of protection?
Meyer M; Malherbe DC; Bukreyev A
Trends Microbiol; 2019 Jan; 27(1):8-16. PubMed ID: 30201511
[TBL] [Abstract][Full Text] [Related]
34. Safety, reactogenicity, and immunogenicity of a chimpanzee adenovirus vectored Ebola vaccine in children in Africa: a randomised, observer-blind, placebo-controlled, phase 2 trial.
Tapia MD; Sow SO; Mbaye KD; Thiongane A; Ndiaye BP; Ndour CT; Mboup S; Keshinro B; Kinge TN; Vernet G; Bigna JJ; Oguche S; Koram KA; Asante KP; Gobert P; Hogrefe WR; De Ryck I; Debois M; Bourguignon P; Jongert E; Ballou WR; Koutsoukos M; Roman F;
Lancet Infect Dis; 2020 Jun; 20(6):719-730. PubMed ID: 32199492
[TBL] [Abstract][Full Text] [Related]
35. Enrolling study personnel in Ebola vaccine trials: from guidelines to practice in a non-epidemic context.
Lhomme E; Modet C; Augier A; Faye S; Dabakuyo-Yonli TS; Levy-Marchal C; D'Ortenzio E; Yazdanpanah Y; Chêne G; Beavogui AH; Richert L;
Trials; 2019 Jul; 20(1):422. PubMed ID: 31296253
[TBL] [Abstract][Full Text] [Related]
36. Safety and immunogenicity of DNA vaccines encoding Ebolavirus and Marburgvirus wild-type glycoproteins in a phase I clinical trial.
Sarwar UN; Costner P; Enama ME; Berkowitz N; Hu Z; Hendel CS; Sitar S; Plummer S; Mulangu S; Bailer RT; Koup RA; Mascola JR; Nabel GJ; Sullivan NJ; Graham BS; Ledgerwood JE;
J Infect Dis; 2015 Feb; 211(4):549-57. PubMed ID: 25225676
[TBL] [Abstract][Full Text] [Related]
37. Ebola vaccine trials: progress in vaccine safety and immunogenicity.
Matz KM; Marzi A; Feldmann H
Expert Rev Vaccines; 2019 Dec; 18(12):1229-1242. PubMed ID: 31779496
[No Abstract] [Full Text] [Related]
38. Implementation of accelerated research: strategies for implementation as applied in a phase 1 Ad26.ZEBOV, MVA-BN-Filo two-dose Ebola vaccine clinical trial in Uganda.
Kitonsa J; Ggayi AB; Anywaine Z; Kisaakye E; Nsangi L; Basajja V; Nyantaro M; Watson-Jones D; Shukarev G; Ilsbroux I; Robinson C; Kaleebu P
Glob Health Action; 2020 Dec; 13(1):1829829. PubMed ID: 33073737
[TBL] [Abstract][Full Text] [Related]
39. Considerations for use of Ebola vaccine during an emergency response.
Walldorf JA; Cloessner EA; Hyde TB; MacNeil A;
Vaccine; 2019 Nov; 37(48):7190-7200. PubMed ID: 28890191
[TBL] [Abstract][Full Text] [Related]
40. Immunomonitoring of human responses to the rVSV-ZEBOV Ebola vaccine.
Medaglini D; Siegrist CA
Curr Opin Virol; 2017 Apr; 23():88-94. PubMed ID: 28460340
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
